CA3188345A1 - Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease - Google Patents
Combination of zibotentan and dapagliflozin for the treatment of chronic kidney diseaseInfo
- Publication number
- CA3188345A1 CA3188345A1 CA3188345A CA3188345A CA3188345A1 CA 3188345 A1 CA3188345 A1 CA 3188345A1 CA 3188345 A CA3188345 A CA 3188345A CA 3188345 A CA3188345 A CA 3188345A CA 3188345 A1 CA3188345 A1 CA 3188345A1
- Authority
- CA
- Canada
- Prior art keywords
- dapagliflozin
- pharmaceutically acceptable
- acceptable salt
- zibotentan
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063050147P | 2020-07-10 | 2020-07-10 | |
| US63/050,147 | 2020-07-10 | ||
| US202163196793P | 2021-06-04 | 2021-06-04 | |
| US63/196,793 | 2021-06-04 | ||
| PCT/IB2021/056177 WO2022009163A1 (en) | 2020-07-10 | 2021-07-09 | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3188345A1 true CA3188345A1 (en) | 2022-01-13 |
Family
ID=76959008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3188345A Pending CA3188345A1 (en) | 2020-07-10 | 2021-07-09 | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US11730735B2 (https=) |
| EP (1) | EP4178578A1 (https=) |
| JP (1) | JP7814368B2 (https=) |
| KR (1) | KR20230038234A (https=) |
| CN (2) | CN119386017A (https=) |
| AU (2) | AU2021305983B2 (https=) |
| BR (1) | BR112023000406A2 (https=) |
| CA (1) | CA3188345A1 (https=) |
| CL (1) | CL2023000097A1 (https=) |
| CR (1) | CR20230083A (https=) |
| DO (1) | DOP2022000301A (https=) |
| IL (1) | IL299568A (https=) |
| MX (1) | MX2023000276A (https=) |
| PE (1) | PE20230778A1 (https=) |
| PH (1) | PH12023550025A1 (https=) |
| TW (1) | TWI900606B (https=) |
| UY (1) | UY39321A (https=) |
| WO (1) | WO2022009163A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022009163A1 (en) * | 2020-07-10 | 2022-01-13 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease |
| AU2023321653A1 (en) * | 2022-08-12 | 2025-03-27 | Astrazeneca Ab | Combination therapies for treatment of cirrhosis with portal hypertension |
| UY40633A (es) * | 2023-02-08 | 2024-07-31 | Astrazeneca Ab | Combinación de zibotentán y dapagliflozina para el tratamiento de la enfermedad renal crónica con pr |
| WO2025133907A1 (en) * | 2023-12-18 | 2025-06-26 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of microvascular angina |
| WO2025163559A1 (en) | 2024-02-01 | 2025-08-07 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for use for the treatment of hypertension |
| WO2025261457A1 (zh) * | 2024-06-21 | 2025-12-26 | 深圳信立泰药业股份有限公司 | 内皮素a(eta)受体拮抗剂联用sglt-2抑制剂的医药用途 |
| WO2026078068A1 (en) * | 2024-10-09 | 2026-04-16 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease and liver fibrosis |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA58494C2 (uk) | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| EP2545920A1 (en) | 2007-08-22 | 2013-01-16 | Abbott GmbH & Co. KG | Therapy for complications of diabetes |
| US9364458B2 (en) | 2013-07-08 | 2016-06-14 | Abbvie Inc. | Stabilized pharmaceutical dosage forms comprising atrasentan |
| US8962675B1 (en) | 2013-09-12 | 2015-02-24 | Abbvie Inc. | Atrasentan mandelate salts |
| FI3658140T3 (fi) | 2017-02-27 | 2025-08-12 | Idorsia Pharmaceuticals Ltd | Aprositentaanin yhdistelmiä muiden vaikuttavien ainesosien kanssa resistentin verenpainetaudin hoitamiseksi |
| CN111405899B (zh) | 2017-11-30 | 2025-05-16 | 爱杜西亚药品有限公司 | 用于治疗内皮素相关疾病的4-嘧啶磺酰胺衍生物与sglt-2抑制剂的组合 |
| US20210338648A1 (en) * | 2018-10-01 | 2021-11-04 | Astrazeneca Ab | Methods and compositions for reducing serum uric acid |
| IL297208A (en) | 2020-04-10 | 2022-12-01 | Chinook Therapeutics Inc | Treatment methods for diabetic kidney disease |
| WO2022009163A1 (en) * | 2020-07-10 | 2022-01-13 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease |
| US12409186B2 (en) | 2020-07-27 | 2025-09-09 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
-
2021
- 2021-07-09 WO PCT/IB2021/056177 patent/WO2022009163A1/en not_active Ceased
- 2021-07-09 PE PE2023000028A patent/PE20230778A1/es unknown
- 2021-07-09 MX MX2023000276A patent/MX2023000276A/es unknown
- 2021-07-09 TW TW110125259A patent/TWI900606B/zh active
- 2021-07-09 PH PH1/2023/550025A patent/PH12023550025A1/en unknown
- 2021-07-09 CA CA3188345A patent/CA3188345A1/en active Pending
- 2021-07-09 BR BR112023000406A patent/BR112023000406A2/pt unknown
- 2021-07-09 KR KR1020237004545A patent/KR20230038234A/ko active Pending
- 2021-07-09 IL IL299568A patent/IL299568A/en unknown
- 2021-07-09 CN CN202411625959.4A patent/CN119386017A/zh active Pending
- 2021-07-09 JP JP2023501052A patent/JP7814368B2/ja active Active
- 2021-07-09 EP EP21742896.0A patent/EP4178578A1/en active Pending
- 2021-07-09 CR CR20230083A patent/CR20230083A/es unknown
- 2021-07-09 CN CN202180049043.7A patent/CN115803028A/zh active Pending
- 2021-07-09 AU AU2021305983A patent/AU2021305983B2/en active Active
- 2021-07-09 US US17/371,162 patent/US11730735B2/en active Active
- 2021-07-12 UY UY0001039321A patent/UY39321A/es unknown
-
2022
- 2022-12-29 DO DO2022000301A patent/DOP2022000301A/es unknown
-
2023
- 2023-01-10 CL CL2023000097A patent/CL2023000097A1/es unknown
- 2023-06-23 US US18/213,601 patent/US12121517B2/en active Active
-
2024
- 2024-07-05 US US18/764,612 patent/US12409174B2/en active Active
- 2024-07-17 AU AU2024204913A patent/AU2024204913A1/en active Pending
-
2025
- 2025-08-11 US US19/296,221 patent/US20260027112A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12023550025A1 (en) | 2024-03-11 |
| CN115803028A (zh) | 2023-03-14 |
| BR112023000406A2 (pt) | 2023-01-31 |
| TWI900606B (zh) | 2025-10-11 |
| AU2024204913A1 (en) | 2024-08-01 |
| EP4178578A1 (en) | 2023-05-17 |
| US20240358698A1 (en) | 2024-10-31 |
| IL299568A (en) | 2023-02-01 |
| JP2023541766A (ja) | 2023-10-04 |
| US20260027112A1 (en) | 2026-01-29 |
| CN119386017A (zh) | 2025-02-07 |
| US11730735B2 (en) | 2023-08-22 |
| US20230364077A1 (en) | 2023-11-16 |
| TW202216147A (zh) | 2022-05-01 |
| AU2021305983A1 (en) | 2023-03-02 |
| WO2022009163A1 (en) | 2022-01-13 |
| AU2021305983B2 (en) | 2024-05-16 |
| CL2023000097A1 (es) | 2023-09-01 |
| CR20230083A (es) | 2023-05-16 |
| PE20230778A1 (es) | 2023-05-09 |
| US20220023295A1 (en) | 2022-01-27 |
| UY39321A (es) | 2022-01-31 |
| JP7814368B2 (ja) | 2026-02-16 |
| US12409174B2 (en) | 2025-09-09 |
| DOP2022000301A (es) | 2023-01-31 |
| KR20230038234A (ko) | 2023-03-17 |
| US12121517B2 (en) | 2024-10-22 |
| MX2023000276A (es) | 2023-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3188345A1 (en) | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease | |
| Cohen | Neutrophilic dermatoses: a review of current treatment options | |
| IL274943B1 (en) | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases | |
| US9993517B2 (en) | Methods and compositions for preserving retinal ganglion cells | |
| EP2533785B1 (en) | Treatment of loss of sense of touch with saxitoxin derivatives | |
| ES3060532T3 (en) | Sublingual formulation of riluzole | |
| EP2087891A3 (en) | Pharmaceutical compositions for treating lymphoma | |
| EP2460522A3 (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
| JP2017019846A (ja) | 点眼剤 | |
| EP2803360A1 (en) | Treatment of pulmonary hypertension with topiramate in combination with a type v phosphodiesterase inhibitor | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| KR20110132371A (ko) | Ｒｄｅａ１１９／ｂａｙ ８６９７６６을 포함하는 특정 암의 치료를 위한 제약 조합물 | |
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| AU2007218709A1 (en) | Prophylactic or therapeutic agent for cerebral ischemia or cerebral ischemic reperfusion injury in stroke | |
| CO5251425A1 (es) | Metodo y composiciones para administrar taxanos oralmente a pacientes humanos | |
| RU2334517C2 (ru) | Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство | |
| MX2025002126A (es) | Tratamientos con dosis unitarias fijas del anticuerpo actrii | |
| Nishimura | Daptomycin-related rhabdomyolysis complicated by severe hyperkalemia and acute kidney injury | |
| CA2450915A1 (en) | Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure | |
| WO2021262562A3 (en) | Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof | |
| WO2012046772A1 (ja) | リンパ浮腫予防治療剤 | |
| RU2004137109A (ru) | Комбинация блокатора рецептора ангиотензина ii и бетаблокатора для вторичной профилактики инфаркта миокарда | |
| JPH11286455A (ja) | 骨髄異形成症候群治療薬 | |
| JP2023547475A5 (https=) | ||
| RU2326668C2 (ru) | Способ лечения рецидивирующего птеригиума |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250625 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250625 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250625 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250828 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250828 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250828 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251009 |